In January 2023, Dr. Ingrid Rauter was appointed Head of R&D and CMO and thus manages all activities with internal and external experts in order to achieve the development goals set for VCC-001 and the pipeline.
Dr. Ingrid Rauter brings deep research, development and medical affairs expertise and joins Vaccentis from her most recent position as global medical lead of the inflammation pipeline at Amgen Inc.
